Versant Venture Management, LLC
CIK 1560009 · View on SEC EDGAR ↗
- Portfolio value
- $162.6M
- Positions
- 8
- As of
- June 30, 2026
Portfolio value QoQ: +15.0% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 6
- Effective number of positions
- 3.4
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.0% Est. buys $0 · sells $11,866,302
Median holding: 5.0 quarters Tracked Q4 2024–Q2 2026 · 72.7% still held
- New positions
- 0
- Increased
- 0
- Decreased
- 1
- Closed
- 2
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: -0.3% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 99.7% · Options excluded: 0.0%
Sector breakdown
Full portfolio 8 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $76,974,876 | 47.34% | 3,180,780 | $24,651,045 | |||
| IPSC Century Therapeutics, Inc. - Common Stock | $29,806,967 | 18.33% | 12,166,109 | $2,311,561 | |||
| JBIO Jade Biosciences, Inc. - Common Stock | $22,037,418 | 13.55% | 991,783 | $599,647 | Down ×1 | ||
| LENZ LENZ Therapeutics, Inc. - Common Stock | $15,091,124 | 9.28% | 2,656,888 | $-9,219,401 | |||
| CTNM Contineum Therapeutics, Inc. - Common stock | $8,893,673 | 5.47% | 542,628 | $1,806,951 | |||
| CRSP CRISPR Therapeutics AG - Common Shares | $8,117,243 | 4.99% | 148,831 | $1,037,352 | |||
| SKYE Skye Bioscience, Inc. - Common Stock | $1,391,941 | 0.86% | 2,007,704 | $158,006 | |||
| TPST Tempest Therapeutics, Inc. - Common Stock | $299,447 | 0.18% | 269,772 | $-142,979 | |||
| No matches | |||||||
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| RPTX | Dec. 31, 2025 | 2,646,657 | $4,658,116 | No longer tracked |
| ADVM | Dec. 31, 2025 | 506,821 | $2,295,899 | No longer tracked |